CN106456713A - Fgf‑18化合物给药方案 - Google Patents

Fgf‑18化合物给药方案 Download PDF

Info

Publication number
CN106456713A
CN106456713A CN201580020532.4A CN201580020532A CN106456713A CN 106456713 A CN106456713 A CN 106456713A CN 201580020532 A CN201580020532 A CN 201580020532A CN 106456713 A CN106456713 A CN 106456713A
Authority
CN
China
Prior art keywords
fgf
compound
cartilage
weeks
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580020532.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·H·雷德尔
H·焦耳林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN106456713A publication Critical patent/CN106456713A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580020532.4A 2014-02-20 2015-02-20 Fgf‑18化合物给药方案 Pending CN106456713A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (1)

Publication Number Publication Date
CN106456713A true CN106456713A (zh) 2017-02-22

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580020532.4A Pending CN106456713A (zh) 2014-02-20 2015-02-20 Fgf‑18化合物给药方案
CN201580020536.2A Pending CN106232622A (zh) 2014-02-20 2015-02-20 Fgf‑18化合物给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580020536.2A Pending CN106232622A (zh) 2014-02-20 2015-02-20 Fgf‑18化合物给药方案

Country Status (25)

Country Link
US (2) US9724388B2 (https=)
EP (2) EP3119417B1 (https=)
JP (2) JP6431082B2 (https=)
KR (2) KR102410988B1 (https=)
CN (2) CN106456713A (https=)
AR (2) AR099558A1 (https=)
AU (2) AU2015220773B2 (https=)
BR (2) BR112016018696A2 (https=)
CA (1) CA2938791A1 (https=)
DK (2) DK3107559T3 (https=)
ES (2) ES2689071T3 (https=)
HR (2) HRP20181570T1 (https=)
HU (1) HUE040350T2 (https=)
IL (2) IL247084B (https=)
LT (2) LT3107559T (https=)
MX (2) MX2016010871A (https=)
NZ (1) NZ723148A (https=)
PL (2) PL3107559T3 (https=)
PT (2) PT3107559T (https=)
RS (2) RS57853B1 (https=)
RU (2) RU2691946C2 (https=)
SG (2) SG11201606502YA (https=)
SI (2) SI3107559T1 (https=)
WO (2) WO2015124727A1 (https=)
ZA (2) ZA201605547B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111164429A (zh) * 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的炎性生物标志物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｇｆ−１８を含むインプラント
HUE040350T2 (hu) 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
JP7671249B2 (ja) * 2019-02-08 2025-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 変形性関節症が急速に進行するリスクがある患者の治療
KR102920449B1 (ko) * 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505787A (zh) * 2006-08-25 2009-08-12 阿雷斯贸易股份有限公司 软骨障碍的治疗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2493840T3 (es) * 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
ES2706848T3 (es) * 2004-07-06 2019-04-01 Zymogenetics Inc Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
HRP20120643T1 (hr) 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
CN103547580B (zh) * 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｇｆ−１８を含むインプラント
HUE040350T2 (hu) 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505787A (zh) * 2006-08-25 2009-08-12 阿雷斯贸易股份有限公司 软骨障碍的治疗

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111164429A (zh) * 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的炎性生物标志物

Also Published As

Publication number Publication date
ES2689071T3 (es) 2018-11-08
RU2700582C2 (ru) 2019-09-18
JP6431083B2 (ja) 2018-11-28
EP3107559A1 (en) 2016-12-28
EP3119417B1 (en) 2018-07-11
HRP20181570T1 (hr) 2018-11-30
AR099558A1 (es) 2016-08-03
RS57709B1 (sr) 2018-12-31
ZA201605548B (en) 2018-12-19
ZA201605547B (en) 2019-09-25
BR112016018685A2 (pt) 2017-10-17
SI3119417T1 (sl) 2018-11-30
AU2015220773A1 (en) 2016-09-01
ES2688551T3 (es) 2018-11-05
SI3107559T1 (sl) 2018-11-30
IL247083B (en) 2019-09-26
US9724388B2 (en) 2017-08-08
JP2017512194A (ja) 2017-05-18
WO2015124727A1 (en) 2015-08-27
AU2015220773B2 (en) 2020-10-08
WO2015124731A1 (en) 2015-08-27
LT3107559T (lt) 2018-10-25
PL3107559T3 (pl) 2019-01-31
JP6431082B2 (ja) 2018-11-28
HRP20181572T1 (hr) 2018-11-30
PL3119417T3 (pl) 2019-01-31
AU2015220777B2 (en) 2020-10-22
IL247083A0 (en) 2016-09-29
PT3119417T (pt) 2018-10-31
SG11201606502YA (en) 2016-09-29
CN106232622A (zh) 2016-12-14
KR20160116000A (ko) 2016-10-06
BR112016018696A2 (pt) 2017-10-17
KR102410988B1 (ko) 2022-06-17
AU2015220777A1 (en) 2016-09-01
US9889179B2 (en) 2018-02-13
US20170072017A1 (en) 2017-03-16
CA2938791A1 (en) 2015-08-27
NZ723148A (en) 2022-08-26
NZ723139A (en) 2022-12-23
LT3119417T (lt) 2018-10-25
MX2016010871A (es) 2016-11-17
KR20160116001A (ko) 2016-10-06
US20170056474A1 (en) 2017-03-02
PT3107559T (pt) 2018-10-31
DK3119417T3 (en) 2018-10-22
RS57853B1 (sr) 2018-12-31
HUE040350T2 (hu) 2019-03-28
AR099510A1 (es) 2016-07-27
IL247084B (en) 2019-09-26
MX2016010872A (es) 2016-11-17
CA2938793A1 (en) 2015-08-27
EP3107559B1 (en) 2018-07-11
RU2691946C2 (ru) 2019-06-19
DK3107559T3 (en) 2018-10-15
RU2016137292A (ru) 2018-03-21
IL247084A0 (en) 2016-09-29
JP2017507142A (ja) 2017-03-16
EP3119417A1 (en) 2017-01-25
SG11201606505UA (en) 2016-09-29
RU2016137292A3 (https=) 2018-09-17
KR102410986B1 (ko) 2022-06-17
RU2016137289A3 (https=) 2018-10-19
RU2016137289A (ru) 2018-03-21

Similar Documents

Publication Publication Date Title
CN106456713A (zh) Fgf‑18化合物给药方案
CN101505787B (zh) 软骨障碍的治疗
RU2745453C2 (ru) Комбинированная композиция, содержащая соединение fgf-18
CA2938793C (en) Fgf-18 compound dosing regimen
HK1231754A1 (zh) Fgf-18化合物给药方案
HK1231895A1 (en) Fgf-18 compound dosing regimen
HK1129852A (en) Treatment of cartilage disorders
HK1129852B (en) Treatment of cartilage disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231754

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231754

Country of ref document: HK